Gross profit margin were at 61.1 per cent
Dr Reddy’s Laboratories (DRL) announced its consolidated financial results for the quarter ended June 30, 2015 under International Financial Reporting Standards (IFRS). . The consolidated revenues were at Rs 37.6 billion, showing a year-on-year growth of seven per cent. The gross profit margin were at 61.1 per cent, improved by 180 bps over last year, the research and development spend were at Rs 4.4 billion. Selling, general and administrative (SG&A) expenses were at Rs 11 billion, showing a marginal year-on-year increase. EBITDA for Q1 FY 16 were at Rs 9.9 billion, 26 per cent of revenues, year-on-year growth of 12 per cent. Profit after tax for Q1 FY 16 were at Rs 6.3 billion, 17 per cent of revenues, year-on-year growth of 14 per cent.
GV Prasad, Co-chairman and Chief Executive Officer, DRL, said, “Our first quarter results, with YoY growth of seven per cent in topline and 14 per cent in bottom line, reflects healthy performance. We were able to achieve these results despite limited new launches and headwinds in the form of currency devaluation in key emerging markets. As we continue to further strengthen our product portfolio and drive new launches, we are well positioned for the next phase of our growth.”